Results of Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
-
2,541 consecutive patients were included in the analyses with a median age of 64, 51% male, 56% African American
-
52% of patients had BMI greater than or equal to 30
Overall crude mortality rates were equal to 18.1% in the cohort.
- 13.5% (hydroxychorloquine only)
- 20.1% (hydroxychorloquine + azithromycin)
- 22.4% (azithromycin alone)
- 26.4% (no drug, p<0.001)
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Methods for Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
Statistical analysis methods for Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
Results of Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
Discussion for Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
Studies in favor of using Hydroxychloroquine as an intervention to COVID-19
Results of Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
Learn After
Mortality in Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
Kaplan–Meier survival curves for Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
Matched pair analysis for Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19